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Background: DNA methylation analysis is useful for investigation of male fertility in mammals, whereas the reliance
on tissues limits the research on human. We have previously found the presence of high concentration of cell-free
seminal DNA (cfsDNA) in human semen. We proposed that some testis and epididymis-specific methylated promoters
could be detected in human cfsDNA, and thus hold promise as noninvasive epigenetic biomarkers for male infertility,
of which most cases are caused by defects in testicular sperm production or epididymal sperm maturation.
Results: The ejaculate of successfully vasectomized men does not contain any secretion from testis and epididymis.
Here we compared genome-wide promoter methylation profiles in cfsDNA between health donors and post-
vasectomy men. Promoters of 367 testis and epididymis-specific hypomethylated genes and 134 hypermethylated
genes were identified. Subsequent validation by Methyl-DNA immunoprecipitation and MethyLight analysis confirmed
the result of promoter microarray. Gene Ontology analysis revealed many genes involved in male reproduction.
Conclusion: We detected the testis and epididymis-specific methylated promoters in human cfsDNA, which may be
used for noninvasive epigenetic biomarkers for the study and diagnosis of male infertility.
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Cell-free nucleic acids, including DNA and RNA, exist
ubiquitously as cell-free or being absorbed at the cell sur-
face of living organisms [1]. They are found to be released
via apoptotic or necrotic cells, and be actively secreted by
living cells [1,2]. Cell-free DNA, as a type of cell-free nu-
cleic acids, can be isolated from various human body fluids
including blood plasma [3,4], urine [5], cerebrospinal fluid
[6], bronchoalveolar lavage fluid [7], amniotic fluid [8],
and seminal plasma [9,10]. The isolated cell-free DNA can
be used to examine DNA integrity, microsatellite instabil-
ity, loss of heterozygosity, mutations, polymorphisms, and
DNA methylation [2]. In recent years, considerable atten-
tion has been paid to taking advantage of tissue or cell-
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reproduction in any medium, provided the orwhich represents one of the most promising approaches
for detection and prognosis of cancers, and prenatal diag-
nosis [2,4,8].
Cell-free seminal DNA (cfsDNA) has been detected in
human semen [10]. Our previous work has isolated
cfsDNA and described its characteristics [9]. Given that
human ejaculate is a mixture secreted from bilateral testes,
epididymides, seminal vesicles, bulbourethral glands, and
the prostate [11], cfsDNA should contain DNA epigenetic
information of these organs. Moreover, these DNA epi-
genetic information should be undetectable in the blood,
because DNA should not pass the physical barrier be-
tween the blood and the male reproduction system includ-
ing blood-testis barrier and blood-epididymis barrier.
DNA epigenetic modifications are essential for sperm-
atogenesis. Remethylation occurs from the prosperma-
togonia stage onwards and results in mature spermatozoa
with an adequate DNA methylation pattern [12]. The
methylation status of some genes is changed in some con-
ditions that cause male infertility [13]. We presumed that
the promoters of testis and epididymis-specific methylated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Number of the testis and epididymis-specific hypo- and
hypermethylated promoters in cfsDNA. T/E refers to testis and
epididymis-specific. The number on the top of each column denotes
the quantity of promoters.
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infertility, because most conditions with male infertility
are disordered in spermatogenesis and sperm maturation
[14,15], which occur in testis and epididymis, respectively.
In addition, environmental chemicals may cause sper-
matogenic defects and sperm motility abnormality via epi-
genetic changes [16,17]. So we reasoned that the testis and
epididymis-specific methylated promoters can also be
used for revealing the epigenetic mechanism of male infer-
tility by chemicals.
However, the epigenetic information of testis and epididy-
mis in cfsDNA is still unclear. Although only 10% human
ejaculate is secreted by testis and epididymis [11], we can
still hope to detect DNA epigenetic information of testis
and epididymis-specific methylated genes in semen. Firstly,
germ cells undergo a high level of apoptosis and get into
seminiferous tubule during spermatogenesis in testis, and
the epithelium releases amounts of microvesicles into glan-
dular lumen via apocrine secretion in epididymis. These
characteristics may bring a large quantity of DNA from the
testis and epididymis into the semen. Our previous study
also indicated this possibility [9]. Secondly, many testis-
specific methylated promoters were found in human testis
[18-22].
The present study compared the genome-wide pro-
moter methylation profiles of cfsDNA between healthy
donors and vasectomized men. The differentially methyl-
ated promoters should be testis and epididymis-specific
because the ejaculate of a successfully vasectomized man
does not contain secretion from testis and epididymis. As
a result, we determined for the first time the testis and
epididymis-specific promoter methylation profile in
cfsDNA, which may provide noninvasive epigenetic bio-
markers for male infertility in humans.
Results
Quantity of cfsDNA in healthy subjects and vasectomized men
The ejaculate of a man with successfully post-vasectomy
(PV) should not contain any secretion from the testis and
epididymis. Successful vasectomy was confirmed by the
absence of sperm in ejaculate and no detection of DDX4
mRNA in cell-free seminal RNA by RT-PCR [23]. In order
to find whether there are a large amount of DNA originat-
ing from testis and epididymis in seminal plasma, we mea-
sured the cfsDNA concentration of healthy donors
with normozoospermia (Nor) and men with PV. The aver-
aged cfsDNA concentration of Nor (n = 12) was 1.23 ±
0.32 μg/ml seminal plasma, with ranges from 0.72 to
1.73 μg/ml. In contrast, the averaged cfsDNA concentra-
tion of PV (n = 11) was 0.33 ± 0.09 μg/ml seminal plasma,
with ranges from 0.22 to 0.48 μg /ml. The averaged
cfsDNA concentration of Nor was about quadruple of PV,
which suggests more than 70% cfsDNA originates from
testis and epididymis.Genome-wide detection of the testis and epididymis-
specific hypo- and hypermethylated promotors by
Methyl-DNA immunoprecipitation (MeDIP) microarray
High concentration of cfsDNA in human semen and high
proportion of cfsDNA from testis and epididymis make it
possible to identify the epigenetic information of cfsDNA
derived from testis and epididymis. We examined the
methylation profiles of 18,028 human promoters in the
seminal plasma of Nor and PV with the NimbleGem
HG18 Refseq promoter array. Finally, we identified 4111
promoters in the cfsDNA of Nor and PV. Comparative
analysis of the data of 4111 promoter methylation peaks
in Nor and PV, we found 9.71% was testis and epididymis-
specific hypomethylated promoters, and 3.53% was testis
and epididymis-specific hypermethylated promoters
(Figure 1). The multiple promoters from the same gene
were summarized. Finally, we found 367 testis and
epididymis-specific hypomethylated genes, and 134 testis
and epididymis-specific hypermethylated genes. All genes
are listed in Additional file 1.
Considering the methylation peakscore value of pro-
moters is associated with the probability of hypo- or
hypermethylation, we summarized the distribution of
peakscore value about the promoters of hypo- and hyper-
methylated genes so as to choose the reliable testis and
epididymis-specific methylated promoters for the clinical
research of male infertility. We found they showed the
similar distribution (Figure 2). In the testis and epididymis-
Figure 2 The distribution of methylation peakscore value about
the testis and epididymis-specific methylated promoters in
cfsDNA. The histogram indicates the distribution of testis and
epididymis-specific hypo- and hypermethylated promoters
according to the peakscore value, the number on the top of each
column denotes the quantity of promoters in each range of
peakscore value.
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was between 3.0 and 3.5, and in the testis and epididymis-
specific hypermethylated promoters, the percentage
was 79.31%.
Validation of the MeDIP microarray results
To validate the dependability of MeDIP microarray data,
the promoters of 10 testis and epididymis-specific meth-
ylated genes were analyzed by MeDIP-real time quantita-
tive PCR, and of other 10 genes were analyzed by
MethyLight. As shown in Figure 3, single-gene MeDIP re-
sult was concordant with the promoter methylation
microarray, except for PEG10 and CLPB. The methylation
level of GAPDH was less than 0.0026% in Nor and less
than 0.0045% in PV. The methylation level of H19 was
59.30% in Nor and 43.47% in PV. MeDIP-real time quanti-
tative PCR result is showed in Additional file 2. As for the
other 10 promoters measured by MethyLight, nine pro-
moters were successfully determined, except the failure of
MCM10 amplification. Eight testis and epididymis-specific
methylated promoters were consistent with the promoter
array besides NCK2 (Additional file 3). In the detected 9
promoters, the difference of ΔCT between the unmeth-
ylated leukocyte DNA and fully methylated leukocyte
DNA was all greater than 5.0. The result of MethyLight is
showed in Additional file 4.
The functions of testis and epididymis-specific hypo- and
hypermethylated genes
Aiming to find the relationship between these testis and
epididymis-specific methylated promoters and the biologyof male reproduction, and suggest potential biomarkers
for research and diagnosis of male infertility, Gene Ontol-
ogy was used to analyze the biological processes and mo-
lecular functions of these genes. The most significant
annotation clusters of enriched gene sets were inferred
from functional annotation analysis with the testis and
epididymis-specific hypo- or hypermethylated genes.
The biological processes of gene set analysis are shown
in Tables 1 and 2. The testis and epididymis-specific
hypomethylated genes were enriched for genes involved in
sexual reproduction, ion transport, organic acid transport,
negative regulation of transport, and defense response
(Table 1). In contrast, the testis and epididymis specific
hypermethylated genes were significantly related to regula-
tion of cellular protein metabolic process, translation, cel-
lular cation homeostasis, regulation of ubiquitin-protein
ligase activity during mitotic cell cycle and regulation of
epidermal growth factor receptor activity (Table 2).
The molecular functions are shown in Additional file 5
and Additional file 6, the testis and epididymis-specific
hypomethylated genes were enriched for genes relevant to
structural molecule activity, channel activity, calcium ion
binding, cytokine activity (Additional file 5); the hyper-
methylated genes were enriched for genes correlated to
RNA binding and peptidase activity (Additional file 6).
Discussion
The present study identified genome-wide testis and
epididymis-specific promoter methylation information in
cfsDNA, aiming to develop noninvasive epigenetic bio-
markers for male infertility. For this purpose we compared
promoter methylation profiles in the cfsDNA of Nor and
PV. Overall, our results demonstrate that there are a num-
ber of promoters of testis and epididymis-specific hypo-
and hypermethylated genes in cfsDNA, thus providing a
foundation for developing noninvasive biomarkers for
studying the epigenetic mechanism and clinical diagnosis of
male infertility, of which most conditions are impaired tes-
ticular spermatogenesis and epididymal sperm maturation.
In our study, the semen samples of successful vasectomy
are indispensable, because these samples do not contain
DNA originating from testis and epididymis owing to the
ligation of vas deferens, which makes it possible to screen
the testis or epididymis-specific methylated promoters.
Although several previous studies reported that vasectomy
could change the mRNA and protein expression of epi-
didymis and impair the spermatogenesis of testis and in-
duce aberrant DNA methylation at imprinted genes in
testicular sperm [24-27], there are no reports in the litera-
ture describing the change of DNA methylation status in
human seminal vesicles, bulbourethral glands and the
prostate after vasectomy. Therefore, comparative analysis
of promoter methylation information in the cfsDNA of
Nor and PV can identify variations in methylation profiles
Figure 3 Comparing the methylation status of 10 promoters between NimbleGen HG18 Promoter Array (A) and MeDIP-real time
quantitative PCR (B). A, The data of log2(IP/Input) graph shows the methylation signal intensity in the Promoter Array. The bars of upper row
and lower row of lo2(IP/Input) graph in each amplifiable promoter fragments denote the methylation signal intensity of each probe in the
cfsDNA of PV and Nor, respectively; B, MeDIP-real time quantitative PCR results. Each bar represents the methylation level of amplifiable promoter
fragments analyzed by the relative quantity between IP and Input DNA.
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likely testis and epididymis tissue specific and potential
biomarkers for male fertility.
Another rationale for identification testis and epididymis-
specific methylated promoters is the high contribution
of releasing or secretion of these organs to cfsDNA con-
centration. We previously found that concentration
of cfsDNA is much higher than other body fluids, and
proposed the high contribution of testicular apoptosis to
cfsDNA [9]. In the present study, averaged cfsDNA con-
centration in Nor was about quadruple of PV, indicating
that cfsDNA is mostly originated from testis and epididy-
mis. Considering spontaneous apoptosis happens in 75%
of germ cell, which would develop to mature spermatozoa
in mammalian, and the renewal of epididymal epithelium
is slow [28,29], it is more likely that the apoptosis of germ
cell in testis is the primary origin of cfsDNA from testis
and epididymis.Moreover, to ensure the reliability of testis and
epididymis-specific methylated promoters identified by pro-
moter methylation profile, we excluded some factors influ-
encing the methylation profile of cfsDNA and kept the
control subjects and vasectomized donors as matched as
possible. Some previous studies reported that aberrant DNA
methylation occurred in distinct diseases [30]. In addition,
environmental chemicals [16,17], age [31] and lifestyle fac-
tors [32] can also affect the DNA methylation of human tis-
sues. Therefore, to meet inclusion criteria, both Nor and PV
groups were screened for potential confounding conditions
such as inflammation of reproduction organs, genetic dis-
ease, potential occupational exposure, obesity and smoking
and excess alcohol consumption.
By the microarray of promoter methylation, we identi-
fied the promoters of 367 testis and epididymis-specific
hypomethylated genes and 134 testis and epididymis-
specific hypermethylated genes. Comparing our result
Table 1 GO analysis of biological processes with testis
and epididymis-specific hypomethylated genes
Gene Ontology Term (GO:ID) Number
of genes
ESa
Ion transport (GO:0006811) 21 1.19
Phosphorylation (GO:0016310) 21 1.05
Cell adhesion (GO:0007155) 20 1.28
Defense response (GO:0006952) 18 1.26
Protein complex biogenesis (GO:0070271) 15 1.12
Sexual reproduction (GO:0019953) 14 1.14
Ectoderm development (GO:0007398) 11 2.47
Nitrogen compound biosynthetic process
(GO:0044271)
11 1.15




Organic acid transport (GO:0015849) 7 1.28
Regulation of hormone levels (GO:0010817) 7 1.25
Muscle contraction (GO:0006936) 7 1.22
Negative regulation of transport (GO:0051051) 6 1.01
a ES stands for Enrichment Score value of GO identifiers (ID), it equals
(−log10P). P stands for the significance testing value of GO ID.
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human testis, we can determine some testis-specific meth-
ylated genes. Currently, only one study has globally ana-
lyzed the human testis-specific promoter methylation to
identify testis-specific hypomethylated genes [18]. Totally
12 genes with promoter hypomethylation in this report
are found in our results. Among them, MORC1 is related
to spermatogenesis [33]; ELF5 is involved in cell prolifera-
tion [34]; PRAME is associated with the regulation of
apoptosis [35]; SPACA3 is correlated to the sperm-egg
recognition [36]. But some testis-specific hypomethylated
genes are inconsistent with our result. It may be mainly
due to the differences in the comparison and source of
DNA. The previous report [18] compared DNAs betweenTable 2 GO analysis of biological processes with testis
and epididymis-specific hypermethylated genes
Gene Ontology Term (GO:ID) Number
of genes
ES
Cell surface receptor linked signal transduction
(GO:0007166)
20 1.51
Sensory perception of smell (GO:0007608) 9 2.13
Regulation of cellular protein metabolic process
(GO:0032268)
8 1.44
Translation (GO:0006412) 6 1.17
Cellular cation homeostasis (GO:0030003) 5 1.06
Regulation of ubiquitin-protein ligase activity during
mitotic cell cycle (GO:0051437)
3 1.10
Regulation of epidermal growth factor receptor
activity (GO:0007176)
2 1.03testis and other tissues, whereas we compared cfsDNA
between vasectomized men and healthy donors. In
addition, the testicular DNA originates from spermato-
genic cells, Sertoli cell and Leydig cell. However, testis and
epididymis-specific cfsDNA should be mainly released by
the apoptotic germ cells including spermatogonia, sper-
matocytes and spermatids [37], and epididymal epithe-
lium. Some testis and epididymis-specific hypomethylated
genes relevant to the spermatogenesis in our result, such
as DNMT3L, HSF1, MSH4, THEG, SOHLH1 and CIB1
[38], cannot be found in the methylation profile of testis
tissue owing to the interference of Sertoli cell and Leydig
cell [18]. Some other reports studied promoter methyla-
tion of individual genes in testis [19,20]. Our result con-
firmed the testis-specific hypomethylated genes including
MAGEA1 [19] and ANKRD30A [20].
The result of single-gene MeDIP-real time quantitative
PCR and MethyLight analysis confirmed the reliability of
our microarray data. Among the 19 promoters which were
successfully determined, sixteen are consistent with the
result of promoter methylation microarray. The other 3
promoters tested as false positives on the microarray,
which may be due to the possibly inefficient or non-
specific detection of individual probes on the microarray
and normalization artifacts during data processing. The
failure of measurement of MCM10 may be due to the in-
appropriate primers and probe. Several previous studies
concurred with our result of single-gene MeDIP and
MethyLight analysis: the hypomethylated promoters of
CLPB, PRAME, DAZ1 MORC1, and NCK2 were con-
firmed in human testis [18]; the hypomethylated pro-
moters of HOXA5, GML, PEG10 and SNURF were
identified in human sperm [15,39]. Methylation level of
H19 in single-gene MeDIP analysis is lower than human
spermatocytes and spermatid, but it is similar with sperm-
atogonia and somatic cell [40], which suggests that most
of H19 in cfsDNA originates from the spermatogonia and
epithelial cell of male reproduction organs.
To further understand the potential function of testis and
epididymis-specific hypo- and hypermethylated genes, and
apply these potential epigenetic markers, we carried out
Gene Ontology analysis with the testis and epididymis-
specific hypomethylated genes and hypermethylated genes,
respectively. Out of the biological processes of testis and
epididymis-specific hypomethylated genes, it is obviously
that sexual reproduction is consistent with the function of
testis because the process of spermatogenesis takes place in
testis and involves the development of mitotically growing
spermatogonia into meiotic spermatocytes that give rise to
haploid spermatids, and subsequently differentiate into ma-
ture sperm [41]. Other biological processes, such as ion
transport, organic acid transport and negative regulation of
transport, participate in the reabsorption and excretion of
epididymis [14], the biological process of defense response
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epididymis [42]. On the other hand, the biological processes
of testis and epididymis-specific hypermethylated genes in-
volve in regulation of cellular protein metabolic process,
regulation of ubiquitin-protein ligase activity during mitotic
cell cycle and regulation of epidermal growth factor recep-
tor activity, which may be the apoptotic inducement of
spermatogenic cell because of either low expression or si-
lence of these hypermethylated genes.
Conclusion
Taken together, we have firstly identified the genome-wide
testis and epididymis-specific hypo- and hypermethylated
promoters in cfsDNA. Totally 367 hypomethylated gene
promoters and 134 hypermethylated gene promoters
were proposed as testis and epididymis-specific, and can be
detected in cfsDNA. The methylation modification of testis
or epididymis-specific promoters is important for the
spermatogenesis and sperm mature [12], and the aberrant
methylation change of these promoters correlates with male
infertility, carcinogenesis and development [12,16,17,43].
Therefore, the genome-wide testis or epididymis-specific
methylated promoters in cfsDNA can be used as the poten-
tial epigenetic biomarkers for noninvasive study and diag-




All normozoospermic semen samples (n = 12) were col-
lected from specimens remaining after routine
andrological analysis. PV semen samples were acquired
from adults (n = 11) who underwent vasectomy within
5 years. PV was confirmed by the absence of sperm in
ejaculate and no detection of DDX4 mRNA in cell-free
seminal RNA by RT-PCR [23]. PV semen with any ab-
normal parameter other than sperm amounts was ex-
cluded. The semen criteria for Nor were according to
guidelines of WHO (World Health Organization) [44].
The inclusion subjects for each group were 28-40 years
old, the Han nationality, smoking <2 pack per year and
intaking of alcohol <1 drink per week, body mass index
between 18.5 and 24. All individuals had no family his-
tory of genetic diseases, history of autoimmune disor-
ders, malignancy, hyperpyrexia, sexually transmitted
diseases or inflammation of reproductive organs. Indi-
viduals who worked in high temperature environments
or had occupational exposure to toxic chemicals or radi-
ation were also excluded. This study was approved by
the Institutional Review Board, and all participants pro-
vided written informed consent. Semen specimens were
obtained by masturbation after 3-5 days of sexual abstin-
ence and were allowed to liquefy for 30-60 min at room
temperature.CfsDNA isolation and fragmentation
Seminal plasma was obtained by low speed centrifugation
(400 × g for 10 min) to avoid cell lyses and then centrifuged
again at 12, 000 × g for 10 min. The supernatant was care-
fully collected and subjected to cfsDNA extraction, which
was performed as our previous described [9]. To obtain
enough cfsDNA, 2.4 ml seminal plasma in every sample of
8 control subjects and 7 vasectomized men was abstracted.
Concentration and purity of DNA were detected by an
ultraviolet photometer (Biometra, Göttingen, Germany).
DNA size distribution was detected using agarose gel elec-
trophoresis. To reach the requirement of DNA quantity in
promoter methylation microarray, and avoid individual
variation, cfsDNA from 6 Nor and 6 PV were combined to
make “Nor” and “PV” pools, respectively. Concentration of
DNA was assessed by spectrophotometry for MeDIP.
Ultrasonication to a mean fragment size of 200-500 bp was
carried out with the bioruptor (Diagenode) using the fol-
lowing settings: Bioruptor on low, sonication for 10 cycles
of 30 sec on and 30 sec off, and 5 μg DNA in 300 μl TE
buffer. Fragment range was controlled using agarose gel
electrophoresis.
MeDIP and microarray hybridization
MeDIP was performed as previous described with some
modification [45]. Briefly, 4 μg of fragmented DNA was
used for a standard MeDIP assay. After denaturation at 95°
C for 10 min, immunoprecipitation was performed using
4 μg mouse monoclonal antibody against 5-methylcytidine
(1 μg/μl, Diagenode) in a final volume of 500 μl IP
buffer (0.5% NP40, 1.1% Triton X-100, 1.5 mM EDTA,
50 mM Tris-HCl, 150 mM NaCl) at 4°C for 12 h.
Immunoprecipitated complexes were collected with mag-
netic beads (Bangs laboratories. Inc) coupled anti-mouse
IgG (1 μg/μl, Jackson) at 4°C for 2 h, washed with IP buffer
for five times. DNA was purified by phenol-chloroform ex-
traction and ethanol precipitation.
The Input and IP DNA were labeled with cy3- and cy5-
labeled random nonamers, respectively. Labeled DNA from
the Input and IP pools was mixed (Input/IP =1:1, 2 μg) and
hybridized to NimbleGem HG18 Refseq promoter array
(Roche, Germany), which contained all known well-
characterized 18028 RefSeq promoter regions [(from about -
2200 bp to +500 bp of the transcription start sites] totally
covered by 385, 000 probes. Arrays were then washed and
scanned with Axon GenePix 4000B microarray scanner.
The raw data was abstracted as pair files by NimbleScan
v2.5 (Roche-NimbleGen) software. After normalization,
raw data was inputted into SignalMap software (v1.9,
Roche-NimbleGen) to observe and evaluate the differential
methylation peaks between Nor and PV cfsDNA.
A customized peak-finding algorithm supplied by
NimbleGen was using to analyze methylation data from
MeDIP-microarray (NimbleScan v2.5; Roche-Nimble-Gen)
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data was generated, the modified algorithm was applied to
carry out the one-sided Kolmogorov-Smirnov test on se-
veral adjacent probes using sliding windows to predict
enriched regions across the microarray. The algorithm was
set with specified parameters [sliding window width,
750 bp; minimal probes per peak, 2; P value (after -log10
transformation) minimum cutoff, 2; maximum spacing
between nearby probes within peak, 500 bp] [47]. Then,
the identified methylation peaks were mapped to ge-
nomic transcripts. Processed data was imported into
microsoft office excel 2003 for further analysis. Pro-
moters with significant methylation change were re-
vealed according to the difference of methylation
peaks in the cfsDNA of Nor and PV.
Criteria for seminal promoters derived from testis and
epididymis
The candidates of seminal promoters derived from testis
and epididymis were selected based on the followong cri-
teria: the peakscore value (-log10p) of testis and epididymis-
specific hypomethylated promoters is more than 3.0
(P < 0.001) in the vasectomized men and less than 2.0
(P > 0.01) in the Nor donors; on the contrary, the peakscore
value of testis and epididymis-specific hypermethylated pro-
moters is more than 3.0 in the Nor donors and less than 2.0Table 3 The positional relationship of primer, methylation pe
validation








PEG10 Paternally expressed 10 NM_015068 chr7:941240
−94124086
MORC1 MORC family CW-type zinc finger 1 NM_014429 chr3:1103193
−11031938
GML Glycosylphosphatidylinositol
anchored molecule like protein
NM_002066 chr8:1439134
−14391341






SNURF SNRPN upstream reading frame NM_005678 chr15:227512
−22751314
MSH4 MutS homolog 4 NM_002440 chr1:760351
−76035135
DAZ1 Deleted in azoospermia 1 NM_004081 chrY:237543
−23754389
CLPB Caseinolytic peptidase B homolog NM_030813 chr11:718244
−71824504in the vasectomized men. These promoters with obviously
differential peakscore in Nor and PV are supposed to be re-
leased or secreted from testis and epididymis, because the
ejaculate of a successfully vasectomized men does not con-
tain secretion from testis and epididymis.
Real-time quantitative PCR
Primers were designed using primer 5.0 and beacon de-
signer 7.0 software and the quality was controlled by PCR
and BLAT functions of the UCSC Genome Browser (http://
genome.ucsc.edu/). Enrichment of a specific fragment in
the MeDIP eluate was detected and quantified relative to
the Input DNA by real-time quantitative PCR on an
Mx3000P thermocycler (Stratagene) using the SYBRW
Premix Ex Taq™ II (TaKaRa Code: DRR820A) according to
the manufacturer’s description. We used GAPDH as the
negative control and H19 as the positive control to certifi-
cate the specificity of MeDIP because GAPDH promoter is
normally unmethylated and H19 promoter is normally
100% methylation in spermatid and 50% methylation
in somatic cells [40]. Primer sequences were given in
Additional file 7 and the positional relationship of primer,
methylation peak and transcript start site in 10 genes se-
lected for validation was shown in Table 3. Cycling condi-
tions were as follows: denaturation (95°C for 30 sec),
amplification and quantification (95°C for 5 sec, 58°C forak and transcript start site (TSS) in genes selected for
location(5′-3′) Peak location Strand Position(TSS = +1)
Reverse Forword 5′ Reverse 5′
79 chr22:21231496 chr22:21231050 - 251 54
−21231479 −21231499
64 chr7:94124274 chr7:94123914 + 492 702
−94124252 −94124663
61 chr3:110319519 chr3:110319258 - 322 164
1 −110319495 −110320007
00 chr8:143913599 chr8:143912618 + 182 381
9 −143913577 −143913667
41 chr7:27151029 chr7:27150312 - −1029 −1217
−27151008 −27151961
22 chr21:44506560 chr21:44506027 - 205 −33
−44506540 −44508076
95 chr15:22751430 chr15:22751327 + 68 203
−22751410 −22751676
17 chr1:76035360 chr1:76035117 + −100 143
−76035338 −76035566
71 chrY:23754582 chrY:23754045 - 256 45
−23754560 −23754994
86 chr11:71824650 chr11:71823916 - −1270 −1434
−71824631 −71824774
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ment at the end of segment) repeated 40 times, a melting
curve program (60-95°C with a heating rate of 0.1°C/sec
and continuous fluorescence measurement) and a cooling
step to 4°C.
The methylation level of selected promoters in cfsDNA
is calculated according to the relative quantity of MeDIP
DNA to Input DNA in amplified fragments. Computing
the relative quantity of each MeDIP DNA fraction to In-
put DNA requires to account for the difference of concen-
tration in prepared DNA samples, so the percentage of IP/
Input = 2-[Ct(IP)–Ct(Input)] × (dilution factor of Input DNA) ×
100% (Ct, cycle threshold). The size of products was identi-
fied by electrophoretically separated on 2.0% agarose gels.Bisulfite treatment of cfsDNA and MethyLight analysis
The seminal cfsDNA of 4 Nor and 4 PV was recovered as
our previous described [9]. Sodium bisulfite conversion of
cfsDNA was performed using EpiTect Bisulfite (Qiagen,
Hilden, Germany). Following sodium bisulfite conversion,
cfsDNA was analyzed using the MethyLight technique
[48]. The primers and probe for β-ACTIN were previously
reported [49], which served as a reference to normalize
the quantity of input DNA. The other 10 sets of primers
and probes, which were designed specifically by beacon
designer 7.0 for bisulfite-converted cfsDNA, were used
to detect the methylation level of testis and epididymis-
specific hypo- or hypermethylated promoters. The se-
quences of primers and probes are given in Additional
file 8. Specificity of the reactions for methylated DNA
was confirmed separately using M.SssI-treated human
leukocyte DNA (NEB, M0226L, USA) and unmethylated
leukocyte DNA. TaqMan PCRs with primers and probe
specific for the bisulfite-converted methylated promoter
sequence of a particular locus and with the β-ACTIN
reference primers and probe were performed separately.
The percentage of methylation at a specific locus is to
be 2-ΔΔCt × 100%, where ΔΔCT = (CTTarget-CTReference)
sample-(CTTarget -CTReference)fully methylated DNA [50].Annotation of the testis and epididymis-specific hypo-
and hypermethylated genes
For exploring potential shared functional of testis and
epididymis-specific hypo- and hypermethylated genes, we
used Gene Ontology (http://david.abcc.ncifcrf.gov/sum-
mary.jsp) from Functional Annotation Tools (http://david.
abcc.ncifcrf.gov/tools.jsp) for Gene Ontology analysis and
identified the statistical significance of the overlap with
each Gene Ontology functional category using the Fisher
exact test. Benjamini-Hochberg multiple testing correc-
tion was used to control false discovery rate, and the genes
were classified into three main categories: cellular compo-
nent, biological process, and molecular function.Additional files
Additional file 1: The lists of testis and epididymis-specific hypo- and
hypermethylated genes.
Additional file 2: The Ct value of 10 validated genes in IP and Input
DNA identified by MeDIP-real time quantitative PCR and the
relative quantity of IP/Input in the cfsDNA of Nor and PV.
Additional file 3: The methylation status of 9 promoters analyzed
by MethyLight. Box plots illustrating the methylation level of amplifiable
promoter fragments measured by MethyLight between the bisulfite-
converted cfsDNA of 4 Nor and 4 PV. Methylation targets are promoter
sequences specific to the 3 testis and epididymis-specific
hypermethylated genes (CHRFAM7A, USP28 and NCK2) and 6 testis and
epididymis-specific hypomethylated genes (ERRFI1, FBRS, GLTPD1, HSF1,
VPS16 and ZNF623) identified by promoter methylation microarray. The
boxes represent the quartiles and whiskers mark the range of the data,
the horizontal line in the boxes denotes the median.
Additional file 4: The Ct value of 9 validated genes identified by
MethyLight analysis and the relative methylation level of target
genes in the cfsDNA of Nor and PV.
Additional file 5: GO enrichment analysis of the testis and
epididymis-specific hypomethylated genes. Each bar represents the
enrichment score (ES) of significant GO terms. The ES of each GO terms is
larger than 1.0. The number in brackets denotes the quantity of genes
involved in each GO term.
Additional file 6: GO enrichment analysis of the testis and
epididymis-specific hypermethylated genes. Each bar represents the
enrichment score (ES) of significant GO terms. The ES of each GO terms is
larger than 1.0. The number in brackets denotes the quantity of genes
involved in each GO term.
Additional file 7: Primers used for MeDIP-real time quantitative PCR.
Additional file 8: Primers and probes used for MethyLight analysis.Abbreviations
cfsDNA: Cell-free seminal DNA; MeDIP: Methyl-DNA immunoprecipitation;
PV: Post-vasectomy; Nor: Normozoospermia.Competing interests
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